|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||144.63 kg/mol g·mol−1|
|(what is this?)|
Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density. Blosozaumab has been studied with regards to the treatment of osteoporosis in both men and postmenopausal women. Clinical trials with Blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect.
Blosozumab was developed by Eli Lilly and Company.
- World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).[permanent dead link]
- McColm, Juliet; Hu, Leijun; Womack, Theresa; Tang, Cheng Cai; Chiang, Alan Y (2014-04-01). "Single- and Multiple-Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal Women". Journal of Bone and Mineral Research. 29 (4): 935–943. doi:10.1002/jbmr.2092. ISSN 1523-4681. PMID 23996473.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.|